CardieX : Consolidation/Split - CDX

January 14, 2022 at 11:42 am IST

Notification of Consolidation/Split

Announcement Summary

For personal use only

Entity name

CARDIEX LIMITED

Applicable security for the reorganisation

CDX	ORDINARY FULLY PAID
CDXAJ	PERFORMANCE RIGHTS
CDXAQ	OPTION EXPIRING 11-JUN-2026 EX $0.08
CDXAN	OPTION EXPIRING 26-FEB-2024 EX $0.05
CDXAM	OPTION EXPIRING 15-JAN-2024 EX $0.05
CDXAO	OPTION EXPIRING 15-FEB-2026 EX $0.05
CDXAP	OPTION EXPIRING 15-FEB-2026 EX $0.08
Announcement Type
New Announcement
Date of this announcement
14/1/2022
Reorganisation type
Security consolidation

Trading in the post consolidation or split +securities commences on a deferred settlement basis

18/2/2022

Record Date

21/2/2022

Issue Date

28/2/2022

Additional Information

None.

Notification of Consolidation/Split

1 / 7

Notification of Consolidation/Split

Refer to below for full details of the announcement

For personal use only

Notification of Consolidation/Split

2 / 7

Notification of Consolidation/Split

Announcement Details

only
	Part 1 - Entity and announcement details
		1.1 Name of +Entity
		CARDIEX LIMITED
		1.2 Registered Number Type		Registration Number
use	ABN
	81113252234
1.3 ASX issuer code


		CDX
		1.4 The announcement is
personal	New announcement
1.5 Date of this announcement

		14/1/2022
		1.6 Securities affected by the consolidation or split
		ASX +Security Code	ASX +Security Description
		CDX	ORDINARY FULLY PAID
		CDXAJ	PERFORMANCE RIGHTS
For	CDXAQ	OPTION EXPIRING 11-JUN-2026 EX $0.08
CDXAN	OPTION EXPIRING 26-FEB-2024 EX $0.05

		CDXAM	OPTION EXPIRING 15-JAN-2024 EX $0.05
		CDXAO	OPTION EXPIRING 15-FEB-2026 EX $0.05
		CDXAP	OPTION EXPIRING 15-FEB-2026 EX $0.08

Notification of Consolidation/Split

3 / 7

Notification of Consolidation/Split

	Part 2 - Approvals

only	2.1	Are any of the below approvals required for the consolidation or split before business day 0 of the timetable?
	Security holder approval
	Court approval
	Lodgement of court order with +ASIC
	ACCC approval
	FIRB approval
	Another approval/condition external to the entity required to be given/met before business day 0 of the
	timetable for the consolidation or split.
		Yes
		2.2	Approvals
use	Approval/Condition	Date for determination	Is the date estimated or	Approval
+Security holder approval	16/2/2022		actual?	received/condition met?

			Estimated

		Comments

		As required by section 254H of the Corporations Act, the consolidation of capital is conditional on the approval of
		shareholders with such approval being sought at an EGM to be held on 16 February 2022.
personal
17/2/2022
	P rt 3 - Consolidation or split timetable and details
		3.1	+Record date
		21/2/2022
		3.2	Date of +security holder meeting
		16/2/2022
		3.2a Effective date of consolidation or split
		16/2/2022
For	3.3	Last day for trading in the pre consolidation or split +securities
3.4	Trading in the post consolidation or split +securities commences on a deferred settlement basis.

		18/2/2022
		3.5	Record date
		21/2/2022

3.6 First day for entity to update its register and to send holding statements to +security holders reflecting the change in the number of +securities they hold.

22/2/2022

Notification of Consolidation/Split

4 / 7

Notification of Consolidation/Split

3.7 Last day for entity to update its register and send holding statements to +security holders reflecting the change in the number of +securities they hold and to notify ASX that this has occurred. (+Issue Date)

		28/2/2022
		3.8 Trading starts on a normal T+2 basis
only	1/3/2022
3.9 First settlement of trades conducted on a +deferred settlement basis and on a normal T+2 basis

		3/3/2022
	Part 4 - Event type and details

use	4.1 The event is

		+Security consolidation
		4.1a Consolidation ratio: the +securities will be consolidated on the basis that every
		10
		(pre-consolidation) +securities will be consolidated into
personal	1
(post-consolidation) +security (/ies).

		4.2 Scrip fraction rounding
		Fractions rounded up to the next whole number
	Part 5 - +Securities on issue before and after consolidation or split

		5.1 +Securities on issue before and after the consolidation or split
		ASX +Security Code	ASX +Security Description
		CDX	ORDINARY FULLY PAID
For	Quoted/unquoted	Number on issue pre	Number on issue post	Estimate/Actual
Quoted	consolidation or split	consolidation or split	Estimated


				1,099,022,516	109,902,252
		ASX +Security Code	ASX +Security Description
		CDXAJ	PERFORMANCE RIGHTS
		Quoted/unquoted	Number on issue pre	Number on issue post	Estimate/Actual
		Unquoted	consolidation or split	consolidation or split	Actual

				176,500,000	17,650,000

Notification of Consolidation/Split

5 / 7

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Cardiex Limited published this content on 14 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2022 06:11:02 UTC.

	1st Jan change	Capi.
CARDIEX LIMITED	-54.07%	13.71M
THERMO FISHER SCIENTIFIC	+7.87%	223B
DANAHER CORPORATION	+11.83%	195B
INTUITIVE SURGICAL, INC.	+18.87%	144B
BOSTON SCIENTIFIC CORPORATION	+30.03%	111B
SIEMENS HEALTHINEERS AG	+2.32%	65.19B
EDWARDS LIFESCIENCES CORPORATION	+14.15%	53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	50.28B
AGILENT TECHNOLOGIES, INC.	+6.60%	44.15B
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	36.45B

1st Jan change

Capi.

CARDIEX LIMITED

-54.07%

13.71M

THERMO FISHER SCIENTIFIC

+7.87%

223B

DANAHER CORPORATION

+11.83%

195B

INTUITIVE SURGICAL, INC.

+18.87%

144B

BOSTON SCIENTIFIC CORPORATION

+30.03%

111B

SIEMENS HEALTHINEERS AG

+2.32%

65.19B

EDWARDS LIFESCIENCES CORPORATION

+14.15%

53.02B

SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

+2.68%

50.28B

AGILENT TECHNOLOGIES, INC.

+6.60%

44.15B

GE HEALTHCARE TECHNOLOGIES INC.

+1.85%

36.45B

Delayed Australian S.E. Other stock markets 06:26:08 29/05/2024 am IST			5-day change	1st Jan Change
0.062 ^AUD	-4.62%		-6.06%	-54.07%

02/04	Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes	MT
02/04	Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5%	MT

Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes	02/04	MT
Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5%	02/04	MT
CARDIEX Secures Higher Credit Facility from C2 Ventures	15/03	MT
CardieX Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024	23/02	CI
CardieX Advances Trade Reinstatement Process with Australian Bourse	02/01	MT
Cardiex Receives Full Settlement of Clinichain Clinical Trial Payments	07/12	MT
Cardiex Limited Announces Mitchell Asset Management Extends Loan Expiration of R&D Facility	20/11	CI
CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director	19/23/19	CI
CardieX Limited Announces Sales Results for the First Quarter September 2023	04/23/04	CI
CardieX Limited Announces Resignation of Jarrod White as Interim Chief Financial Officer	28/23/28	CI
CardieX Limited Announces Resignation of Jarrod White as Executive Director	28/23/28	CI
CardieX Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
CardieX Limited Announces Executive Changes	30/23/30	CI
CardieX Limited Announces Resignation of Reid Yeoman as CFO	30/23/30	CI
CardieX Limited Provides Revenue Guidance for the Fiscal Year 2023	30/23/30	CI
CardieX Limited announced that it expects to receive AUD 4.1 million in funding	30/23/30	CI
CardieX Limited Receives FDA 510(K) Clearance for its Vascular Biometric Monitor - The CONNEQT Pulse	26/23/26	CI
CardieX Secures US FDA Clearance for Blood Pressure Monitoring Device	26/23/26	MT
CardieX Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
CardieX to Raise AU$4.5 Million Via Share Placement	09/23/09	MT
CardieX Subsidiary Secures Loan Facility	06/23/06	MT
CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer	06/23/06	CI
CardieX Unit Signs Clinical Trial Services Deal for Blood Pressure Device	09/22/09	MT
CardieX Announces Significant New Clinical Trial Agreement	09/22/09	CI

CardieX Limited

Equities

CDX

AU0000015729

Advanced Medical Equipment & Technology

CardieX : Consolidation/Split - CDX

Latest news about CardieX Limited

Chart CardieX Limited

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Advanced Medical Equipment & Technology